Treatment of
osteoporosis, as an antiosteoporotic, in the treatment of
bone and mineral disease and disorders, bone metabolism
regulator, blood calcium regulator, and as a diagnostic aid
(pseudohypoparathyroidism; hypocalcemia).
Human rPTH (1-34) has been produced by recombinant
technologies, is now approved, and will soon be available
for the treatment of osteoporosis. It is given subcutaneously,
25 μg/day cyclically for 12 to 18 months, to increase
bone density in individuals with a history of fractures,
severe osteopenia, or osteoporosis. PTHrP (1-36)
has also been synthesized and is in early clinical trials.
Parathyroid hormone (PTH) exerts its effects on bone and kidney cells. This hormone plays a role in calcium homeostasis. PTH is secreted from the chief cells of the parathyroid gland in response to low extracellular calcium levels or higher levels of extracellular phosphate. PTH deficiency or excess PTH are associated with hypoparathyroidism and hyperparathyroidism, respectively.
